Mitochondrial dysfunction is associated with a wide range of human diseases, including neurodegenerative diseases, and is believed to cause or contribute to the etiology of these diseases. These disorders are frequently associated with increased levels of reactive oxygen species. One of the design strategies for therapeutic intervention involves the development of novel small molecules containing redox cores, which can scavenge reactive oxygen radicals and selectively block oxidative damage to the mitochondria. Presently, we describe recent research dealing with multifunctional radical quenchers as antioxidants able to scavenge reactive oxygen radicals. The review encompasses ubiquinone and tocopherol analogs, as well as novel pyri(mi)dinol derivatives, and their ability to function as protective agents in cellular models of mitochondrial diseases.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Weissig V. Targeted drug delivery to mammalian mitochondria in living cells. Expert Opin. Drug Deliv. 2(1), 89–102 (2005).
Medline CASGoogle Scholar
2. Friedman JR, Nunnari J. Mitochondrial form and function. Nature 505(7483), 335–343 (2014).
Medline CASGoogle Scholar
3. Milane L, Trivedi M, Singh A, Talekar M, Amiji M. Mitochondrial biology, targets, and drug delivery. J. Control. Release 207, 40–58 (2015).
Medline CASGoogle Scholar
4. Saraste M. Oxidative phosphorylation at the fin de siècle. Science 283(5407), 1488–1493 (1999).
Medline CASGoogle Scholar
5. Teixeira J, Deus CM, Borges F, Oliveira PJ. Mitochondria: targeting mitochondrial reactive oxygen species with mitochondriotropic polyphenolic-based antioxidants. Int. J. Biochem. Cell Biol. 97, 98–103 (2018).
Medline CASGoogle Scholar
6. Lund M, Melbye M, Diaz LJ, Duno M, Wohlfahrt J, Vissing J. Mitochondrial dysfunction and risk of cancer. Br. J. Cancer 112(6), 1134–1140 (2015).
Medline CASGoogle Scholar
7. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell 125(7), 1241–1252 (2006).
Medline CASGoogle Scholar
8. Wallace DC. Mitochondria and cancer. Nat. Rev. Cancer 12(10), 685–698 (2012).
Medline CASGoogle Scholar
9. Cai Q, Tammineni P. Mitochondrial aspects of synaptic dysfunction in Alzheimer’s disease. J. Alzheimers Dis. 57(4), 1087–1103 (2017).
Medline CASGoogle Scholar
10. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat. Rev. Neurosci. 7(3), 207–219 (2006).
Medline CASGoogle Scholar
11. Rocha M, Apostolova N, Herance JR et al. Perspectives and potential applications of mitochondria-targeted antioxidants in cardiometabolic diseases and type 2 diabetes. Med. Res. Rev. 34(1), 160–189 (2014).
Medline CASGoogle Scholar
12. Kezic A, Spasojevic I, Lezaic V, Bajcetic M. Mitochondria-targeted antioxidants: future perspectives in kidney ischemia reperfusion injury. Oxid. Med. Cell Longev. 2016, 2950503 (2016).
MedlineGoogle Scholar
13. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113), 787–795 (2006). • Important review about the role of mitochondria in the pathogenesis of neurodegenerative diseases.
Medline CASGoogle Scholar
14. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 59(3), 527–605 (1979).
Medline CASGoogle Scholar
15. Reed DJ. Glutathione: toxicological implications. Annu. Rev. Pharmacol. Toxicol. 30, 603–631 (1990).
Medline CASGoogle Scholar
16. Sies H. Strategies of antioxidant defense. Eur. J. Biochem. 215(2), 213–219 (1993).
Medline CASGoogle Scholar
17. Sheng Y, Abreu IA, Cabelli DE et al. Superoxide dismutases and superoxide reductases. Chem. Rev. 114(7), 3854–3918 (2014). • Important review about superoxide dismutases and superoxide reductases to quench ROS.
Medline CASGoogle Scholar
18. Imai H, Nakagawa Y. Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic. Biol. Med. 34(2), 145–169 (2003).
Medline CASGoogle Scholar
19. Yamada Y, Harashima H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv. Drug Deliv. Rev. 60(13–14), 1439–1462 (2008). • This article discussed the key role of mitochondria in living cells, a number of drug delivery systems and mitochondrial-targeted therapeutic strategies.
Medline CASGoogle Scholar
20. Bohr VA. Repair of oxidative DNA damage in nuclear and mitochondrial DNA, and some changes with aging in mammalian cells. Free Radic. Biol. Med. 32(9), 804–812 (2002).
Medline CASGoogle Scholar
21. Zhong H, Yin H. Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: focusing on mitochondria. Redox Biol. 4, 193–199 (2013).
Google Scholar
22. Stadtman ER. Protein oxidation and aging. Free Radic. Res. 40(12), 1250–1258 (2006).
Medline CASGoogle Scholar
23. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186, 1–85 (1990).
Medline CASGoogle Scholar
24. Schapira AH. Mitochondrial involvement in Parkinson’s disease, Huntington’s disease, hereditary spastic paraplegia and Friedreich’s ataxia. Biochim. Biophys. Acta 1410(2), 159–170 (1999).
Medline CASGoogle Scholar
25. Tönnies E, Trushina E. Oxidative stress, synaptic dysfunction, and Alzheimer’s disease. J. Alzheimers Dis. 57(4), 1105–1121 (2017).
MedlineGoogle Scholar
26. Hoye AT, Davoren JE, Wipf P, Fink MP, Kagan VE. Targeting mitochondria. Acc. Chem. Res. 41(1), 87–97 (2008).
Medline CASGoogle Scholar
27. Smith RA, Hartley RC, Murphy MP. Mitochondria-targeted small molecule therapeutics and probes. Antioxid. Redox Signal. 15(12), 3021–3038 (2011). • Addresses strategies for delivery into mitochondria.
Medline CASGoogle Scholar
28. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 47, 629–656 (2007).
Medline CASGoogle Scholar
29. Apostolova N, Victor VM. Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications. Antioxid. Redox. Signal. 22(8), 686–729 (2015).
Medline CASGoogle Scholar
30. Alberts B, Johnson A, Lewis J et al. Molecular biology of the cell: Energy conversion: mitochondria and chloroplast. Molecular Biology of the Cell (4th Edition). Brand M (Ed.). Garland Publishing Inc., NY, USA, 1966–2119 (1994).
Google Scholar
31. Heller A, Brockhoff G, Goepferich A. Targeting drugs to mitochondria. Eur. J. Pharm. Biopharm. 82(1), 1–18 (2012).
Medline CASGoogle Scholar
32. Oyewole AO, Birch-Machin MA. Mitochondria-targeted antioxidants. FASEB J. 29(12), 4766–4771 (2015).
Medline CASGoogle Scholar
33. Wen S, Zhu D, Huang P. Targeting cancer cell mitochondria as a therapeutic approach. Future Med. Chem. 5(1), 53–67 (2013).
CASGoogle Scholar
34. Smith RA, Porteous CM, Coulter CV, Murphy MP. Selective targeting of an antioxidant to mitochondria. Eur. J. Biochem. 263, 709–716 (1999).
Medline CASGoogle Scholar
35. Di Domenico F, Barone E, Perluigi M, Butterfield DA. Strategy to reduce free radical species in Alzheimer’s disease: an update of selected antioxidants. Expert Rev. Neurother. 15(1), 19–40 (2015).
MedlineGoogle Scholar
36. Hurko O. Drug development for rare mitochondrial disorders. Neurotherapeutics 10(2), 286–306 (2013).
Medline CASGoogle Scholar
37. Lukashev AN, Skulachev MV, Ostapenko V et al. Advances in development of rechargeable mitochondrial antioxidants. Prog. Mol. Biol. Transl. Sci. 127, 251–265 (2014).
Medline CASGoogle Scholar
38. Kerr DS. Review of clinical trials for mitochondrial disorders: 1997–2012. Neurotherapeutics 10(2), 307–319 (2013).
Medline CASGoogle Scholar
39. Lyseng-Williamson KA. Idebenone: a review in Leber’s Hereditary Optic Neuropathy. Drugs 76(7), 805–813 (2016). • Important review discussing the use of idebenone for the treatment of Leber’s Hereditary Optic Neuropathy.
Medline CASGoogle Scholar
40. Orsucci D, Mancuso M, Ienco EC, LoGerfo A, Siciliano G. Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr. Med. Chem. 18(26), 4053–4064 (2011).
Medline CASGoogle Scholar
41. Enns GM, Kinsman SL, Perlman SL et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol. Genet. Metab. 105(1), 91–102 (2012).
Medline CASGoogle Scholar
42. Shrader WD, Amagata A, Barnes A et al. a-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging. Bioorg. Med. Chem. Lett. 21(12), 3693–3698 (2011).
Medline CASGoogle Scholar
43. Evans JL, Goldfine ID. Alpha-Lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol. Ther. 2(3), 401–413 (2000).
Medline CASGoogle Scholar
44. Bast A, Haenen GR. Lipoic acid: a multifunctional antioxidant. Biofactors 17(1-4), 207–213 (2003).
Medline CASGoogle Scholar
45. Yoshida H, Yanai H, Namiki Y et al. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev. 12(1), 9–20 (2006).
Medline CASGoogle Scholar
46. Picard M, Wallace DC, Burelle Y. The rise of mitochondria in medicine. Mitochondrion 30, 105–116 (2016).
Medline CASGoogle Scholar
47. Kanabus M, Heales SJ, Rahman S. Development of pharmacological strategies for mitochondrial disorders. Br. J. Pharmacol. 171(8), 1798–1817 (2014).
Medline CASGoogle Scholar
48. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annu. Rev. Pathol. 5, 297–348 (2010).
Medline CASGoogle Scholar
49. Schmidt HH, Stocker R, Vollbracht C et al. Antioxidants in translational medicine. Antioxid. Redox Signal. 23(14), 1130–1143 (2015).
Medline CASGoogle Scholar
50. Dharmaraja AT. Role of reactive oxygen species (ROS) in therapeutics and drug resistance in cancer and bacteria. J. Med. Chem. 60(8), 3221–3240 (2017).
Medline CASGoogle Scholar
51. Birch-Machin MA. The role of mitochondria in ageing and carcinogenesis. Clin. Exp. Dermatol. 31(4), 548–552 (2006).
Medline CASGoogle Scholar
52. Tulah AS, Birch-Machin MA. Stressed out mitochondria: the role of mitochondria in ageing and cancer focusing on strategies and opportunities in human skin. Mitochondrion 13(5), 444–453 (2013).
Medline CASGoogle Scholar
53. Liu Y, Fiskum G, Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 80(5), 780–787 (2002).
Medline CASGoogle Scholar
54. Murphy MP. How mitochondria produce reactive oxygen species. Biochem. J. 417(1), 1–13 (2009).
Medline CASGoogle Scholar
55. Wang Y, Branicky R, Noë A, Hekimi S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J. Cell Biol. 217(6), 1915–1928 (2018).
Medline CASGoogle Scholar
56. Armstrong JS, Khdour O, Hecht SM. Does oxidative stress contribute to the pathology of Friedreich’s ataxia? A radical question. FASEB J. 24(7), 2152–2163 (2010).
Medline CASGoogle Scholar
57. Gutteridge JM. Lipid peroxidation initiated by superoxide-dependent hydroxyl radicals using complexed iron and hydrogen peroxide. FEBS Lett. 172(2), 245–249 (1984).
Medline CASGoogle Scholar
58. Gueven N, Woolley K, Smith J. Border between natural product and drug: comparison of the related benzoquinones idebenone and coenzyme Q10. Redox Biol. 4, 289–295 (2015).
Medline CASGoogle Scholar
59. Food and DrugAdministration. Pharmacy Compounding Advisory Committee (PCAC)Meeting 8-9 May 2017. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm553368.pdf
Google Scholar
60. Kerr DS, deGrauw TJ, Feigenbaum AS. Phase III trial of coenzyme Q10 in mitochondrial disease. ClinicalTrials.gov. NCT00432744 (2007).
Google Scholar
61. Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71(5), 543–552 (2014).
MedlineGoogle Scholar
62. Erb M, Hoffmann-Enger B, Deppe H et al. Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I. PLoS One 7(4), e36153 (2012).
Medline CASGoogle Scholar
63. Montenegro L, Turnaturi R, Parenti C, Pasquinucci L. Idebenone: novel strategies to improve its systemic and local efficacy. Nanomaterials (Basel). 8(2), pii: E87 (2018).
MedlineGoogle Scholar
64. Regulatory action and news. WHO drug information. 27(2), 110–118 (2013).
Google Scholar
65. Hirano M. Study of idebenone in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS). ClinicalTrials.gov Identifier: NCT00887562 (2009).
Google Scholar
66. Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 259(2), 284–291 (2012).
Medline CASGoogle Scholar
67. Klopstock T, Yu-Wai-Man P, Dimitriadis K et al. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain 134(Pt 9), 2677–2686 (2011).
MedlineGoogle Scholar
68. Rudolph G, Dimitriadis K, Büchner B et al. Effects of idebenone on color vision in patients with Leber hereditary optic neuropathy. J. Neuroophthalmol. 33(1), 30–36 (2013).
MedlineGoogle Scholar
69. Duveau DY, Arce PM, Schoenfeld RA et al. Synthesis and characterization of mito Q and idebenone analogues as mediators of oxygen consumption in mitochondria. Bioorg. Med. Chem. 18(17), 6429–6441 (2010).
Medline CASGoogle Scholar
70. Fash DM, Khdour OM, Sahdeo SJ et al. Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection. Bioorg. Med. Chem. 21(8), 2346–2354 (2013).
Medline CASGoogle Scholar
71. Madathil MM, Khdour OM, Jaruvangsanti J, Hecht SM. Synthesis and biological activities of N-(3-Carboxylpropyl)-5-amino-2-hydroxy-3-tridecyl-1,4-benzoquinone and analogues. J. Nat. Prod. 75(12), 2209–2215 (2012).
Medline CASGoogle Scholar
72. Madathil MM, Khdour OM, Jaruvangsanti J, Hecht SM. A structurally simplified analogue of geldanamycin exhibits neuroprotective activity. ACS Med. Chem. Lett. 4(10), 953–957 (2013).
Medline CASGoogle Scholar
73. Lin P, Li S, Wang S, Yang Y, Shi J. A nitrogen-containing 3-alkyl-1,4-benzoquinone and a gomphilactone derivative from Embelia ribes. J. Nat. Prod. 69(11), 1629–1632 (2006).
Medline CASGoogle Scholar
74. McErlean CS, Moody CJ. First synthesis of N-(3-carboxylpropyl)-5-amino-2-hydroxy-3- tridecyl-1,4-benzoquinone, an unusual quinone isolated from Embelia ribes. J. Org. Chem. 72(26), 10298–10301 (2007).
Medline CASGoogle Scholar
75. Whitesell L, Shifrin SD, Schwab G, Neckers LM. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. 52(7), 1721–1728 (1992).
Medline CASGoogle Scholar
76. Kamal-Eldin A, Appelqvist LA. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids 31(7), 671–701 (1996).
Medline CASGoogle Scholar
77. Brigelius-Flohé R, Traber MG. Vitamin E: function and metabolism. FASEB J. 13(10), 1145–1155 (1999).
Medline CASGoogle Scholar
78. Zhang ZW, Xu XC, Liu T, Yuan S. Mitochondrion-permeable antioxidants to treat ROS-burst-mediated acute diseases. Oxid. Med. Cell Longev. 2016, 6859523 (2016).
MedlineGoogle Scholar
79. Kirsh VA, Hayes RB, Mayne ST et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J. Natl Cancer Inst. 98(4), 245–254 (2006).
Medline CASGoogle Scholar
80. Lippman SM, Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 301(1), 39–51 (2009).
Medline CASGoogle Scholar
81. Burton GW, Doba T, Gabe EJ et al. Autoxidation of biological molecules. 4. Maximizing the antioxidant activity of phenols. J. Am. Chem. Soc. 107(24), 7053–7065 (1985). • Discusses the finding that the introduction of electron donating groups not only decreases the O-H bond dissociation enthalpies, but also decreases the ionization potentials.
CASGoogle Scholar
82. Lucarini M, Pedulli GF, Cipollone M. Bond dissociation enthalpy of alpha-tocopherol and other phenolic antioxidants. J. Org. Chem. 59(17), 5063–5070 (1994).
CASGoogle Scholar
83. Wayner DD, Lusztyk E, Ingold KU, Mulder P. Application of photoacoustic calorimetry to the measurement of the O-H bond strength in vitamin E (α- and δ-tocopherol) and related phenolic antioxidants. J. Org. Chem. 61(18), 6430–6433 (1996).
Medline CASGoogle Scholar
84. Lucarini M, Pedrielli P, Pedulli GF, Cabiddu S, Fattuoni C. Bond dissociation energies of O−H bonds in substituted phenols from equilibration studies. J. Org. Chem. 61(26), 9259–9263 (1996).
CASGoogle Scholar
85. Shanks D, Frisell H, Ottosson H, Engman L. Design principles for alpha-tocopherol analogues. Org. Biomol. Chem. 4(5), 846–852 (2006).
Medline CASGoogle Scholar
86. Pratt DA, DiLabio GA, Brigati G, Pedulli GF, Valgimigli L. 5-Pyrimidinols: novel chain-breaking antioxidants more effective than phenols. J. Am. Chem. Soc. 123(19), 4625–4626 (2001). • To increase the stability of highly reactive compounds, these workers reported the studies of incorporation of nitrogen into the phenolic ring in both theory and experiment.
Medline CASGoogle Scholar
87. Tallman KA, Pratt DA, Porter NA. Kinetic products of linoleate peroxidation: rapid β-fragmentation of nonconjugated peroxyls. J. Am. Chem. Soc. 123(47), 11827–11828 (2001).
Medline CASGoogle Scholar
88. Wijtmans M, Pratt DA, Valgimigli L et al. 6-Amino-3-pyridinols: towards diffusion-controlled chain-breaking antioxidants. Angew. Chem. Int. Ed. Engl. 42(36), 4370–4373 (2003).
Medline CASGoogle Scholar
89. Valgimigli L, Brigati G, Pedulli GF et al. The effect of ring nitrogen atoms on the homolytic reactivity of phenolic compounds: understanding the radical-scavenging ability of 5-pyrimidinols. Chem. Eur. J. 9(20), 4997–5010 (2003).
Medline CASGoogle Scholar
90. Wijtmans M, Pratt DA, Brinkhorst J et al. Synthesis and reactivity of some 6-substituted-2,4-dimethyl-3-pyridinols, a novel class of chain-breaking antioxidants. J. Org. Chem. 69(26), 9215–9223 (2004).
Medline CASGoogle Scholar
91. Kim HY, Pratt DA, Seal JR, Wijtmans M, Porter NA. Lipid-soluble 3-pyridinol antioxidants spare alpha-tocopherol and do not efficiently mediate peroxidation of cholesterol esters in human low-density lipoprotein. J. Med. Chem. 48(22), 6787–6789 (2005).
Medline CASGoogle Scholar
92. Nam TG, Rector CL, Kim HY et al. Tetrahydro-1,8-naphthyridinol analogues of alpha-tocopherol as antioxidants in lipid membranes and low-density lipoproteins. J. Am. Chem. Soc. 129(33), 10211–10209 (2007).
Medline CASGoogle Scholar
93. Nam TG, Nara SJ, Zagol-Ikapitte I et al. Pyridine and pyrimidine analogs of acetaminophen as inhibitors of lipid peroxidation and cyclooxygenase and lipoxygenase catalysis. Org. Biomol. Chem. 7(24), 5103–5112 (2009).
Medline CASGoogle Scholar
94. Serwa R, Nam TG, Valgimigli L et al. Preparation and investigation of vitamin B6-derived aminopyridinol antioxidants. Chem. Eur. J. 16(47), 14106–14114 (2010).
Medline CASGoogle Scholar
95. Valgimigli L, Bartolomei D, Amorati R et al. 3-Pyridinols and 5-pyrimidinols: tailor-made for use in synergistic radical-trapping co-antioxidant systems. Beilstein J. Org. Chem. 9, 2781–2792 (2013).
MedlineGoogle Scholar
96. Lu J, Khdour OM, Armstrong JS, Hecht SM. Design, synthesis, and evaluation of an α-tocopherol analogue as a mitochondrial antioxidant. Bioorg. Med. Chem. 18(21), 7628–7638 (2010).
Medline CASGoogle Scholar
97. Khdour OM, Lu J, Hecht SM. An acetate prodrug of a pyridinol-based vitamin E analogue. Pharm. Res. 28(11), 2896–2909 (2011).
Medline CASGoogle Scholar
98. Cai X, Khdour OM, Jaruvangsanti J, Hecht SM. Simplified bicyclic pyridinol analogues protect mitochondrial function. Bioorg. Med. Chem. 20(11), 3584–3595 (2012).
Medline CASGoogle Scholar
99. Arce PM, Goldschmidt R, Khdour OM et al. Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection. Bioorg. Med. Chem. 20(17), 5188–5201 (2012).
Medline CASGoogle Scholar
100. Alam MP, Khdour OM, Arce PM et al. Cytoprotective pyridinol antioxidants as potential therapeutic agents for neurodegenerative and mitochondrial diseases. Bioorg. Med. Chem. 22(17), 4935–4947 (2014).
Medline CASGoogle Scholar
101. Arce PM, Khdour OM, Goldschmidt R, Armstrong JS, Hecht SM. A strategy for suppressing redox stress within mitochondria. ACS Med. Chem. Lett. 2(8), 608–613 (2011).
Medline CASGoogle Scholar
102. Goldschmidt R, Arce PM, Khdour OM et al. Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases. Bioorg Med. Chem. 21(4), 969–978 (2013).
Medline CASGoogle Scholar
103. Khdour OM, Arce PM, Roy B, Hecht SM. An optimized pyrimidinol multifunctional radical quencher. ACS Med. Chem. Lett. 4(8), 724–729 (2013). • One of the important novel MRQs studied to treat the mitochondrial dysfunction.
Medline CASGoogle Scholar
104. Mastroeni D, Khdour OM, Arce PM, Hecht SM, Coleman PD. Novel antioxidants protect mitochondria from the effects of oligomeric amyloid beta and contribute to the maintenance of epigenome function. ACS Chem. Neurosci. 6(4), 588–598 (2015).
Medline CASGoogle Scholar
105. Mastroeni D, Nolz J, Khdour OM et al. Oligomeric amyloid β preferentially targets neuronal and not glial mitochondrial-encoded mRNAs. Alzheimer’s Dement. 14(6), 775–786 (2018). • An important study about a novel MRQ which protected neuronal mitochondria from OAβ-induced mitochondrial changes.
MedlineGoogle Scholar
106. Chevalier A, Alam MP, Khdour OM et al. Optimization of pyrimidinol antioxidants as mitochondrial protective agents: ATP production and metabolic stability. Bioorg. Med. Chem. 24(21), 5206–5220 (2016).
Medline CASGoogle Scholar
107. Chevalier A, Khdour OM, Schmierer M, Bandyopadhyay I, Hecht SM. Influence of substituent heteroatoms on the cytoprotective properties of pyrimidinol antioxidants. Bioorg. Med. Chem. 25(5), 1703–1716 (2017).
Medline CASGoogle Scholar
108. Smith RA, Adlam VJ, Blaikie FH et al. Mitochondria-targeted antioxidants in the treatment of disease. Ann. N Y Acad. Sci. 1147, 105–111 (2008).
Medline CASGoogle Scholar
109. Gane EJ, Weilert F, Orr DW et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 30(7), 1019–1026 (2010).
Medline CASGoogle Scholar
110. Snow BJ, Rolfe FL, Lockhart MM et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov. Disord. 25(11), 1670–1674 (2010).
MedlineGoogle Scholar
111. Zhao K, Zhao GM, Wu D et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem. 279(33), 34682–34690 (2004).
Medline CASGoogle Scholar
112. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br. J. Pharmacol. 171(8), 2029–2050 (2014).
Medline CASGoogle Scholar
113. Szeto HH, Liu S, Soong Y et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J. Am. Soc. Nephrol. 22(6), 1041–1052 (2011).
Medline CASGoogle Scholar
114. Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br. J. Pharmacol. 171(8), 2017–2028 (2014).
Medline CASGoogle Scholar
115. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. Mitochondria-penetrating peptides. Chem. Biol. 15(4), 375–382 (2008).
Medline CASGoogle Scholar
116. Horton KL, Pereira MP, Stewart KM, Fonseca SB, Kelley SO. Tuning the activity of mitochondria-penetrating peptides for delivery or disruption. ChemBioChem. 13(3), 476–485 (2012).
Medline CASGoogle Scholar
117. Chamberlain GR, Tulumello DV, Kelley SO. Targeted delivery of doxorubicin to mitochondria. ACS Chem. Biol. 8(7), 1389–1395 (2013).
Medline CASGoogle Scholar
118. Jean SR, Ahmed M, Lei EK, Wisnovsky SP, Kelley SO. Peptide-mediated delivery of chemical probes and Therapeutics to mitochondria. Acc. Chem. Res. 49(9), 1893–902 (2016).
Medline CASGoogle Scholar
119. Wisnovsky S, Lei EK, Jean SR, Kelley SO. Mitochondrial chemical biology: new probes elucidate the secrets of the powerhouse of the cell. Cell Chem. Biol. 23(8), 917–927 (2016). • An important review about mitochondria-penetrating peptides for delivery into mitochondria.
Medline CASGoogle Scholar
120. Lei EK, Kelley SO. Delivery and release of small-molecule probes in mitochondria using traceless linkers. J. Am. Chem. Soc. 139(28), 9455–9458 (2017).
Medline CASGoogle Scholar
121. Ghosh A, Chandran K, Kalivendi SV et al. Neuroprotection by a mitochondria targeted drug in a Parkinson’s disease model. Free Radic. Biol. Med. 49(11), 1674–1684 (2010).
Medline CASGoogle Scholar
122. Solesio ME, Prime TA, Logan A et al. The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson’s disease. Biochim. Biophys. Acta. 1832(1), 174–182 (2013).
Medline CASGoogle Scholar
123. McManus MJ, Murphy MP, Franklin JL. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J. Neurosci. 31(44), 15703–15715 (2011).
Medline CASGoogle Scholar
124. Ng LF, Grube J, Cheah IK et al. The mitochondria-targeted antioxidant MitoQ extends lifespan and improves health span of a transgenic Caenorhabditis elegans model of Alzheimer disease. Free Radic. Biol. Med. 71, 390–401 (2014).
Medline CASGoogle Scholar
125. Manczak M, Mao P, Calkins MJ et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons. J. Alzheimers Dis. 20(Suppl. 2), S609–S631 (2010).
MedlineGoogle Scholar
126. Dare AJ, Bolton EA, Pettigrew GJ, Bradley JA, Saeb-Parsy K, Murphy MP. Protection against renal ischemia-reperfusion injury in vivo by the mitochondria targeted antioxidant MitoQ. Redox Biol. 5, 163–168 (2015).
Medline CASGoogle Scholar
127. Gioscia-Ryan RA, LaRocca TJ, Sindler AL, Zigler MC, Murphy MP, Seals DR. Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice. J. Physiol. 592(12), 2549–2561 (2014).
Medline CASGoogle Scholar
128. Gioscia-Ryan RA, Battson ML, Cuevas LM, Eng JS, Murphy MP, Seals DR. Mitochondria-targeted antioxidant therapy with MitoQ ameliorates aortic stiffening in old mice. J. Appl. Physiol. 124(5), 1194–1202 (2017).
MedlineGoogle Scholar
129. Rossman MJ, Santos-Parker JR, Steward CAC et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension 71(6), 1056–1063 (2018).
Medline CASGoogle Scholar
130. Zhou J, Wang H, Shen R et al. Mitochondrial-targeted antioxidant MitoQ provides neuroprotection and reduces neuronal apoptosis in experimental traumatic brain injury possibly via the Nrf2-ARE pathway. Am. J. Transl. Res. 10(6), 1887–1899 (2018).
Medline CASGoogle Scholar
131. Gottwald EM, Duss M, Bugarski M et al. The targeted anti-oxidant MitoQ causes mitochondrial swelling and depolarization in kidney tissue. Physiol. Rep. 6, e13667 (2018).
MedlineGoogle Scholar
132. Fink BD, Herlein JA, Yorek MA, Fenner AM, Kerns RJ, Sivitz W. Bioenergetic effects of mitochondrial-targeted coenzyme Q analogs in endothelial cells. J. Pharmacol. Exp. Ther. 342(3), 709–719 (2012).
Medline CASGoogle Scholar
133. Imai Y, Fink BD, Promes JA, Kulkarni CA, Kerns RJ, Sivitz WI. Effect of a mitochondrial-targeted coenzyme Q analog on pancreatic beta-cell function and energetics in high fat fed obese mice. Pharmacol. Res. Perspect. 6, e00393 (2018).
MedlineGoogle Scholar
134. Petri S, Kiaei M, Damiano M et al. Cell- permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 98(4), 1141–1148 (2006).
Medline CASGoogle Scholar
135. Reddy PH, Manczak M, Kandimalla R. Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer’s disease. Hum. Mol. Genet. 26(8), 1483–1496 (2017).
Medline CASGoogle Scholar
136. Cho J, Won K, Wu D et al. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron. Artery Dis. 18(3), 215–220 (2007).
MedlineGoogle Scholar
137. Lee FY, Shao PL, Wallace CG et al. Combined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats. Int. J. Mol. Sci. 19(9), 2782 (2018).
Google Scholar
138. Lu HI, Huang TH, Sung PH et al. Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice. Acta Pharmacol. Sin. 37(5), 589–603 (2016).
Medline CASGoogle Scholar
139. Cai J, Jiang Y, Zhang M et al. Protective effects of mitochondrion-targeted peptide SS-31 against hind limb ischemia-reperfusion injury. J. Physiol. Biochem. 74(2), 335–343 (2018).
Medline CASGoogle Scholar
140. Mizuguchi Y, Chen J, Seshan SV et al. A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am. J. Physiol. Renal Physiol. 295(5), F1545–F1553 (2008).
Medline CASGoogle Scholar
141. Liu S, Soong Y, Seshan SV et al. Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis. Am. J. Physiol. Renal Physiol. 306(9), F970–F980 (2014).
Medline CASGoogle Scholar
142. Thomas DA, Stauffer C, Zhao K et al. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves post transplantation function. J. Am. Soc. Nephrol. 18(1), 213–222 (2007).
Medline CASGoogle Scholar
143. Yang L, Zhao K, Calingasan NY et al. Mitochondria targeted peptides protect against 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid. Redox Signal. 11(9), 2095–2104 (2009).
Medline CASGoogle Scholar
144. Roshanravan B, Liu Z, Ali AS et al. Elamipretide improves skeletal muscle function in elderly subjects: results from a randomized, double-blind, placebo-controlled, single IV dose study. J. Cachexia Sarcopenia Muscle 8, 171 (2017).
Google Scholar
145. Daubert MA, Yow E, Dunn G et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ. Heart Fail. 10(12), e004389 (2017).
Medline CASGoogle Scholar
146. Saad A, Herrmann SMS, Eirin A et al. Phase 2a clinical trial of mitochondrial protection (Elamipretide) during stent revascularization in patients with atherosclerotic renal artery stenosis. Circ. Cardiovasc. Interv. 10(9), e005487 (2017).
Medline CASGoogle Scholar
147. Gibson CM, Giugliano RP, Kloner RA et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur. Heart. J. 37(16), 1296–1303 (2016).
Medline CASGoogle Scholar
148. Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 90(14), e1212–e1221 (2018).
Medline CASGoogle Scholar
149. Hecht S, Armstrong J, Khdour O, Lu J, Arce P. WO2011103536A1 (2011).
Google Scholar
150. Hecht S, Khdour O, Lu J, Arce P. US20130267546A1 (2013).
Google Scholar
151. Hecht S, Khdour O, Lu J, Arce P. US8952025 (2015).
Google Scholar

Vol. 11, No. 13

Metrics

Downloaded 109 times

History

Received 25 September 2018

Accepted 24 April 2019

Published online 30 August 2019

Published in print July 2019

Information

Keywords

Financial & competing interests disclosure

The authors gratefully acknowledge financial support in part by research grants from the United Mitochondrial Disease Foundation (UMDF), and the Friedreich’s Ataxia Research Alliance (FARA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download